63 results on '"Edahiro, Yoko"'
Search Results
2. P1060: THE IMPACT OF POLYCYTHEMIA VERA ON DAILY LIVING, AND SYMPTOM AND TREATMENT PERCEPTION GAPS BETWEEN PATIENTS AND PHYSICIANS: RESULTS OF A CROSS-SECTIONAL SURVEY IN JAPAN
3. A cross-sectional survey of symptoms and daily living among patients with polycythemia vera and their treating physicians in Japan
4. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
5. Evaluation of bone marrow aspirates using the automated hematology analyzer Sysmex XN ‐3000
6. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
7. Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms
8. Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia
9. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
10. Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia
11. Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
12. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study
13. Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non‐neoplastic erythrocytosis patients
14. A pilot study examining the efficacy of hochuekkito for improving quality of life in patients with myeloproliferative neoplasms
15. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
16. Treatment options and pregnancy management for patients with PV and ET
17. Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
18. Author Correction: Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
19. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study
20. Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
21. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations
22. Radiation-Induced Myopathy Developing in a Hodgkin Lymphoma Patient: An Autopsy Case with Systemic Muscle Sampling
23. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis
24. Prevention of thrombotic events in pregnant women with myeloproliferative neoplasms
25. Intravascular large B-cell lymphoma as a recurrence of primary central nervous system lymphoma after chemotherapy: A case report
26. Long-term spontaneous regression of Stage IV diffuse large B-cell lymphoma
27. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome–negative myeloproliferative neoplasms
28. MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations
29. Concomitant Occurrence of Polyclonal Hematopoiesis and Cell-Autonomous Megakaryopoiesis in Triple-Negative Essential Thrombocythemia
30. CREB3L1 Overexpression Can Reliably Discriminate Ph-MPNs from Reactive Cases
31. Difficulty Diagnosing a Brain Tumor during Clinical Maintenance of a Complete Response to anti-HER2 Treatments for Metastatic Breast Cancer: A Case Report
32. Interferon therapy for pregnant patients with essential thrombocythemia in Japan
33. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin
34. Self-limiting pregnancy-associated pure red cell aplasia developing in two consecutive pregnancies: case report and literature review
35. Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations
36. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface
37. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera
38. Specific mechanisms of subarachnoid hemorrhage accompanied by ischemic stroke in essential thrombocythemia: two case reports and a literature review
39. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan
40. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy
41. Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia
42. Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy
43. The Zygosity of JAK2V617F Determines the Disease Entities of Myeloproliferative Neoplasms By Modulating Erythropoiesis but Not Megakaryopoiesis
44. Administration of plasma-derived coagulation factor VIII during the perioperative period of mastectomy for breast cancer with acquired von Willebrand syndrome
45. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation
46. Skewed megakaryopoiesis in human induced pluripotent stem cell‐derived haematopoietic progenitor cells harbouring calreticulin mutations
47. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort
48. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms
49. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria
50. Co-occurrence of hyperleukocytosis and elevated fibrin–fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.